Home > Boards > US OTC > Medical - Drugs > Roche Holding Ltd. (RHHBY)

Roche Hit By European Infringement Charge, XOMA Offers

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
mlkrborn Member Profile
 
Followed By 39
Posts 7,816
Boards Moderated 1
Alias Born 01/04/06
160x600 placeholder
New Hope in the Battle Against Ovarian Cancer NetworkNewsWire - 11/5/2019 8:45:00 AM
Delivering Precision Medicine’s True Potential: Big Data, Artificial Intelligence Identify New Cancer Therapeutics NetworkNewsWire - 10/29/2019 8:45:00 AM
U.K.'s Competition Watchdog Opens Probe into Roche Takeover of Spark Therapeutics Dow Jones News - 10/22/2019 2:46:00 AM
Roche: Phase 3 Study of Tecentriq, Avastin Combination a Success Dow Jones News - 10/21/2019 1:44:00 AM
Roche Says Outlook Is Improving as Revenue Grows Dow Jones News - 10/16/2019 1:48:00 AM
Roche Holding: Results From Tecentriq Study in Bladder Cancer Positive Dow Jones News - 9/30/2019 11:20:00 AM
Genentech Gets FDA Approval for Rituxan in Children With Two Rare Blood Vessel Disorders Dow Jones News - 9/27/2019 2:32:00 PM
Genentech Says Data Positive From Tecentriq Lung Cancer Study Dow Jones News - 9/27/2019 11:20:00 AM
U.K. Regulator to Probe Roche's Acquisition of Spark Therapeutics Dow Jones News - 9/25/2019 2:54:00 AM
Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers NetworkNewsWire - 9/24/2019 8:45:00 AM
Genentech Gets FDA Breakthrough Designation for Gazyva in Lupus Nephritis Dow Jones News - 9/18/2019 6:40:00 AM
Genentech Receives FDA Accelerated Approval for Cancer Treatment Dow Jones News - 8/15/2019 4:36:00 PM
Roche Extends Offer Period for Spark Therapeutics Dow Jones News - 7/31/2019 1:48:00 AM
Roche: CHMP Backs Tecentriq in Extensive-Stage Small-Cell Lung Cancer Dow Jones News - 7/26/2019 10:46:00 AM
Roche Sales Boosted by New Drug Pipeline -- Update Dow Jones News - 7/25/2019 4:14:00 AM
Roche 1st Half Profit, Sales Grew; Raises Full-Year Sales Guidance Dow Jones News - 7/25/2019 1:46:00 AM
Sanofi Gets Exclusive Over-The-Counter Rights to Tamiflu in the US From Roche Dow Jones News - 7/23/2019 1:47:00 AM
AbbVie Says FDA Lifts Partial Hold on Phase 3 Trial Dow Jones News - 6/24/2019 9:38:00 AM
Exelixis: Phase 3 Combination Study for Melanoma Didn't Meet Primary Endpoint Dow Jones News - 6/20/2019 7:37:00 PM
Genentech Gets FDA Priority Review For Rituxan in Children With Rare Blood Vessel Disorders Dow Jones News - 6/12/2019 6:48:00 AM
Genentech's Gazyva Meets Main Endpoints in Lupus Nephritis Study Dow Jones News - 6/11/2019 7:25:00 AM
Roche Says Peter Voser to Step Down as Director; Makes Changes to Executive Committee Dow Jones News - 6/11/2019 1:51:00 AM
Roche's Genentech Gets FDA Priority Approval For Polivy Regimen Dow Jones News - 6/10/2019 12:58:00 PM
Correction to Roche, Spark Therapeutics Article Dow Jones News - 6/10/2019 2:12:00 AM
Roche, Spark Therapeutics Extend Tender Offer Period After FCA Requests More Information Dow Jones News - 6/10/2019 1:52:00 AM
mlkrborn   Wednesday, 10/24/12 06:34:21 PM
Re: None
Post # of 138 
Roche Hit By European Infringement Charge, XOMA Offers Shares: Healthcare Business Recap
By Mark Lawson | More Articles
October 24, 2012
The European Medicines Agency on Wednesday affirmed that it is bringing an infringement procedure against Roche (RHHBY.OB), claiming that the company did not properly check out some 80,000 reports of issues received from U.S. patients and doctors relating to 19 of the firm’s drugs, including the top performers Herceptin and Avastin. Roche could be penalized by as much as 5 percent of its yearly revenues if found guilty.
Shares of United Therapeutics Corporation (NASDAQ:UTHR) go over the cliff on word that on Wednesday the FDA rejected the firm’s new drug application for treprostinil, which is an oral treatment for high blood pressure. The agency said that it is uncertain as to whether another evaluation would help reverse its decision, but did indicate that if the company elects to conduct a further trial, it should consider a fixed dose design and more frequent dosing.
Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.
The drug maker XOMA (NASDAQ:XOMA) will to offer 13.33 million shares of common stock at $3 per share, and intends to use the proceeds for ongoing development and testing of its diabetes treatments gevokizumab and XMet platform, along with other corporate purposes.
Discovery Laboratories (NASDAQ:DSCO) shares sharply dip but rebound on the news that the commercial intro of its Surfaxin liquid medication to treat Infant Respiratory Distress Syndrome will probably be postponed until the second quarter of next year. The launch had previously been planned to occur by the end of the current year.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist